Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab
Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count <1.5 × 109/L that develops >4 weeks after last drug administration, is a known adverse event associated with...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-03-01
|
| Series: | Case Reports in Neurology |
| Online Access: | https://karger.com/article/doi/10.1159/000544749 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321700093591552 |
|---|---|
| author | Casey J. Fealko Morgan N. Rolon-Newton Marisa J.L. Aitken Scott D. Gitlin |
| author_facet | Casey J. Fealko Morgan N. Rolon-Newton Marisa J.L. Aitken Scott D. Gitlin |
| author_sort | Casey J. Fealko |
| collection | DOAJ |
| description |
Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count <1.5 × 109/L that develops >4 weeks after last drug administration, is a known adverse event associated with anti-CD20 monoclonal antibodies, including rituximab and ocrelizumab. Case Presentation: We present the case of a 27-year-old woman who developed severe late-onset neutropenia during her third trimester of pregnancy after treatment with ocrelizumab 6 months prior. Conclusion: Neurologists should be aware of this risk and consider additional hematologic monitoring for pregnant patients who received anti-CD20 therapy as therapies such as G-CSF are available to help prevent serious infections. |
| format | Article |
| id | doaj-art-55dee7b3cb054f5787fde66ea293e5f7 |
| institution | Kabale University |
| issn | 1662-680X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Neurology |
| spelling | doaj-art-55dee7b3cb054f5787fde66ea293e5f72025-08-20T03:49:41ZengKarger PublishersCase Reports in Neurology1662-680X2025-03-01171364010.1159/000544749Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after OcrelizumabCasey J. FealkoMorgan N. Rolon-NewtonMarisa J.L. AitkenScott D. Gitlin Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count <1.5 × 109/L that develops >4 weeks after last drug administration, is a known adverse event associated with anti-CD20 monoclonal antibodies, including rituximab and ocrelizumab. Case Presentation: We present the case of a 27-year-old woman who developed severe late-onset neutropenia during her third trimester of pregnancy after treatment with ocrelizumab 6 months prior. Conclusion: Neurologists should be aware of this risk and consider additional hematologic monitoring for pregnant patients who received anti-CD20 therapy as therapies such as G-CSF are available to help prevent serious infections. https://karger.com/article/doi/10.1159/000544749 |
| spellingShingle | Casey J. Fealko Morgan N. Rolon-Newton Marisa J.L. Aitken Scott D. Gitlin Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab Case Reports in Neurology |
| title | Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab |
| title_full | Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab |
| title_fullStr | Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab |
| title_full_unstemmed | Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab |
| title_short | Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab |
| title_sort | severe late onset neutropenia in a pregnant patient with multiple sclerosis after ocrelizumab |
| url | https://karger.com/article/doi/10.1159/000544749 |
| work_keys_str_mv | AT caseyjfealko severelateonsetneutropeniainapregnantpatientwithmultiplesclerosisafterocrelizumab AT morgannrolonnewton severelateonsetneutropeniainapregnantpatientwithmultiplesclerosisafterocrelizumab AT marisajlaitken severelateonsetneutropeniainapregnantpatientwithmultiplesclerosisafterocrelizumab AT scottdgitlin severelateonsetneutropeniainapregnantpatientwithmultiplesclerosisafterocrelizumab |